Kevin  Chung net worth and biography

Kevin Chung Biography and Net Worth

Chief Medical Officer of SeaStar Medical

Dr. Kevin Chung, a renowned expert in burns, multi-organ support, and extracorporeal therapies, is Chief Medical Officer of SeaStar Medical where he is responsible for the strategy, direction, and execution of the company’s clinical development plans as the company develops and commercializes extracorporeal therapies.

Prior to joining SeaStar Medical, Dr. Chung served as professor and Chair of the Department of Medicine, and professor of Surgery, at the F. Edward Hebert School of Medicine at the Uniformed Services University of the Health Sciences, Bethesda, Maryland. Earlier in his career, he served as Chief of the Department of Medicine at Brooke Army Medical Center in San Antonio. Dr. Chung deployed as the Chief, Intensive Care Unit, for the 86th Combat Support Hospital in Baghdad, Iraq 2008, and as Director, Joint Combat Casualty Research Team in Bagram, Afghanistan 2012.

He is a 1995 graduate of the United States Military Academy at West Point and a 1999 graduate of Georgetown University School of Medicine.

Dr. Chung has authored over 300 peer reviewed manuscripts, reviews, editorials, and book chapters, and has been an invited speaker for over 150 lectures internationally.

What is Kevin Chung's net worth?

The estimated net worth of Kevin Chung is at least $26.62 thousand as of August 22nd, 2025. Dr. Chung owns 5,818 shares of SeaStar Medical stock worth more than $26,617 as of October 2nd. This net worth estimate does not reflect any other investments that Dr. Chung may own. Learn More about Kevin Chung's net worth.

How do I contact Kevin Chung?

The corporate mailing address for Dr. Chung and other SeaStar Medical executives is 3513 Brighton Blvd, Suite 410, Denver, CO, 80216. SeaStar Medical can also be reached via phone at 844-427-8100 and via email at [email protected]. Learn More on Kevin Chung's contact information.

Has Kevin Chung been buying or selling shares of SeaStar Medical?

Kevin Chung has not been actively trading shares of SeaStar Medical during the last quarter. Most recently, on Friday, August 22nd, Kevin Chung bought 1,000 shares of SeaStar Medical stock. The stock was acquired at an average cost of $8.00 per share, with a total value of $8,000.00. Following the completion of the transaction, the insider now directly owns 5,818 shares of the company's stock, valued at $46,544. Learn More on Kevin Chung's trading history.

Who are SeaStar Medical's active insiders?

SeaStar Medical's insider roster includes Jennifer Baird (Director), Kevin Chung (Chief Medical Officer), John Neuman (Director), and Kenneth Van Heel (Director). Learn More on SeaStar Medical's active insiders.

Are insiders buying or selling shares of SeaStar Medical?

In the last year, SeaStar Medical insiders bought shares 3 times. They purchased a total of 2,620 shares worth more than $8,535.50. The most recent insider tranaction occured on August, 18th when CFO Michael Messinger bought 750 shares worth more than $2,452.50. Insiders at SeaStar Medical own 0.7% of the company. Learn More about insider trades at SeaStar Medical.

Information on this page was last updated on 8/18/2026.

Kevin Chung Insider Trading History at SeaStar Medical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/22/2025Buy1,000$8.00$8,000.005,818View SEC Filing Icon  
5/20/2025Buy450$12.50$5,625.001,818View SEC Filing Icon  
9/30/2024Buy100$42.60$4,260.00943View SEC Filing Icon  
5/30/2023Buy50$117.50$5,875.00272View SEC Filing Icon  
4/5/2023Buy15$462.50$6,937.5015View SEC Filing Icon  
See Full Table

Kevin Chung Buying and Selling Activity at SeaStar Medical

This chart shows Kevin Chung's buying and selling at SeaStar Medical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

SeaStar Medical Company Overview

SeaStar Medical logo
SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.
Read More

Today's Range

Now: $4.56
Low: $3.69
High: $4.70

50 Day Range

MA: $3.28
Low: $2.88
High: $3.94

2 Week Range

Now: $4.56
Low: $2.07
High: $7.35

Volume

259,359 shs

Average Volume

106,332 shs

Market Capitalization

$20.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A